Nail Changes with Targeted Antineoplastic Drugs
- 9 February 2021
- book chapter
- other
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switchCancer and Metastasis Reviews, 2013
- Dermatological Adverse Events from BRAF Inhibitors: A Growing ProblemCurrent Oncology Reports, 2013
- Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin InhibitorDermatology, 2012
- Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their managementJournal of the European Academy of Dermatology and Venereology, 2012
- Effect of adapalene on cetuximab-induced painful periungual inflammationJournal of the American Academy of Dermatology, 2011
- Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study groupSupportive Care in Cancer, 2010
- Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitorsBritish Journal of Dermatology, 2009
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective studySupportive Care in Cancer, 2007
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005